# US 2022/0276266 A1 · Lipid-DNA Labeling of Lipid Bilayer Particles for Amplification Quantitation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0276266 A1
- Document ID: US20220276266A1
- Status: Published application
- Kind: A1
- Application number: 17/749,163
- Filed: 2022-05-20
- Published: 2022-09-01
- Earliest claimed: 2019-12-02
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Thomas Robert Carey; Molly Aliza Kozminsky; Lydia L. Sohn
- Web page: https://patentgrep.com/patent/US20220276266A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C12Q 1/6851: Quantitative amplification
- G01N 2458/10: Oligonucleotides as tagging agents for labelling antibodies
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Lipid bilayer particles, such as extracellular vesicles (EVs), are labeled with lipid-tagged single-stranded DNA (ssDNA), which is amplified by polymerase chain reaction (PCR) to quantify particles captured via surface marker interactions or complementary oligonucleotide hybridization.

## Claims

### Claim 1

A method to quantify lipid bilayer particles displaying specific surface antigens, comprising:
(a) labeling the particles with single-stranded DNAs (ssDNAs) each end-labeled with a membrane self-embedding lipid;
(b) specifically capturing different subpopulations of the particles by specific antigen binding or complementary oligonucleotide hybridization;
(c) recovering intact particles by employing a restriction enzyme to release the ssDNA label after the capture;
(d) using quantitative polymerase chain reaction (qPCR) quantification of the ssDNA to yield a quantitative readout that is directly correlated with the number of particles captured;
wherein the labeling step comprises combining the particles with:
i. an anchor oligo comprising: lipid—anchor sequence—adhesion sequence;
ii. a co-anchor oligo comprising: lipid—anchor sequence';
iii. a detection oligo comprising: adhesion sequence'—detection sequence;
wherein the anchor oligo and at least one of the co-anchor oligo and detection oligo comprise complementary restriction sequences;
wherein the ' indicates reverse complement, and the anchor is in opposite orientation from the co-anchor and detection oligos, such that:
the lipids self-embed into the lipid bilayer membrane of the particles and anchor sequences hybridize via complementary base pairing, preventing the anchor oligo from dissociating from the membrane; the adhesion sequences hybridize, capturing the detection oligo onto the particles; and the restriction sequences hybridize, forming a double-stranded restriction site.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anchor oligo and detection oligo comprise the complementary restriction sequences.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anchor oligo and co-anchor oligo comprise the complementary restriction sequences.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
the anchor oligo comprises: lipid—anchor sequence—adhesion sequence—restriction sequence; and
the detection oligo comprises: adhesion sequence'—restriction sequence'—detection sequence.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
the anchor oligo comprises: lipid - anchor sequence - restriction sequence—adhesion sequence; and
the co-anchor oligo comprises: lipid—anchor sequence'—restriction sequence'.

### Claim 6 (depends on 1)

The method of claim 1, wherein:
the anchor oligo comprises: 3′-5′: lipid—anchor sequence—adhesion sequence;
the co-anchor oligo comprises: 5′-3′: lipid—anchor sequence'; and
the detection oligo comprises: 5′-3′: adhesion sequence'—detection sequence.

### Claim 7 (depends on 1)

The method of claim 1, wherein:
the anchor oligo comprises: 5′-3′: lipid—anchor sequence—adhesion sequence;
the co-anchor oligo comprises: 3′-5′: lipid—anchor sequence'; and
the detection oligo comprises: 3′-5′: adhesion sequence'—detection sequence.

### Claim 8 (depends on 1)

The method of claim 1, wherein the anchor sequences are ≥10 nt, the adhesion sequences are ≥10 nt, the restriction sequences are 4-12 nt, and the detection sequence is ≥60 nt.

### Claim 9 (depends on 1)

The method of claim 1, wherein the anchor sequences are 10-300 nt, the adhesion sequences are 10-300 nt, the restriction sequences are 3-12 nt, and the detection sequence is 20-2000 nt.

### Claim 10 (depends on 1)

The method of claim 1, wherein the anchor sequences are 10-100 nt, the adhesion sequences are 10-100 nt, the restriction sequences are 4-12 nt, and the detection sequence is 20-500 nt.

### Claim 11 (depends on 1)

The method of claim 1, wherein the anchor sequences are 10-30 nt, the adhesion sequences are 10-30 nt, the restriction sequences are 4-8 nt, and the detection sequence is 20-100 nt.

### Claim 12 (depends on 1)

The method of claim 1, wherein the lipid is a steroid, lignoceric acid, dialkylphosphoglycerol, or a fatty acid amide.

### Claim 13 (depends on 1)

The method of claim 1, wherein the particles are isolated from a human or animal bodily fluid, a cell culture medium, a medium containing bacteria, or are synthesized.

### Claim 14 (depends on 1)

The method of claim 1, wherein the method quantifies a total number of particles and/or the quantities of different subpopulations of particles in a sample.

### Claim 15 (depends on 1)

The method of claim 1, wherein the capturing step comprises contacting the particles with beads or surfaces functionalized with either a complementary oligonucleotide or a moiety that recognizes and specifically binds a specific antigen under conditions wherein particles displaying the antigen are retained on the beads or surfaces, and particles not displaying the antigen are washed away.

### Claim 16 (depends on 1)

The method of claim 1, in multiplex format, wherein the capturing step comprises contacting subsets of the particles in separate containers, each with beads or surfaces functionalized with a moiety that recognizes a unique, specific antigen, under conditions wherein particles displaying the antigen are retained on the beads or surfaces, and particles not displaying the antigen are washed away.

### Claim 17 (depends on 1)

The method of claim 1, wherein the lipid bilayer particles are extracellular vesicles (EVs).

### Claim 18 (depends on 1)

The method of claim 1, wherein the lipid bilayer particles are enveloped viruses.

### Claim 19 (depends on 1)

The method of claim 1, wherein the lipid bilayer particles are outer membrane vesicles.

### Claim 20 (depends on 1)

The method of claim 1, wherein the lipid bilayer particles are liposomes.
